In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022
1996

Evaluation of RG13022, a Tyrosine Kinase Inhibitor, in Cancer Treatment

Sample size: 10 publication Evidence: low

Author Information

Author(s): HL McLeod, VG Brunton, N Eckardt, MJ Lear, DJ Robins, P Workman, MA Graham

Primary Institution: University of Glasgow

Hypothesis

Can RG13022 effectively inhibit tumor growth in vivo and what are its pharmacokinetics?

Conclusion

RG13022 did not show significant anti-tumor activity in vivo despite its in vitro efficacy.

Supporting Evidence

  • RG13022 showed rapid elimination from plasma with a half-life of 50.4 minutes.
  • Plasma concentrations of RG13022 fell below effective levels within 20 minutes post-injection.
  • RG13022 did not significantly inhibit the growth of established tumors in mice.

Takeaway

Researchers tested a drug called RG13022 to see if it could help stop cancer growth, but it didn't work as well in mice as they hoped.

Methodology

The study involved administering RG13022 to mice with cancer and measuring tumor growth and drug levels in the blood.

Limitations

The rapid elimination of RG13022 from the body may limit its effectiveness, and the study did not evaluate tissue levels of the drug.

Participant Demographics

Athymic female nude mice (MFI nu/nu) weighing between 20 g and 40 g.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication